Pfizer Ltd. Technical Momentum Shifts to Bearish Amid Market Pressure

Price Performance and Market Context

On 24 Mar 2026, Pfizer Ltd. closed at ₹4,538.50, down 4.88% from the previous close of ₹4,771.55. The intraday range was between ₹4,525.90 and ₹4,995.00, reflecting heightened volatility. Despite a 52-week high of ₹5,987.65 and a low of ₹3,742.90, the stock’s recent downward momentum has been pronounced.

Comparatively, Pfizer’s one-week return of -4.44% underperformed the Sensex’s -3.72%. Over the one-month horizon, Pfizer declined 10.50%, slightly outperforming the Sensex’s 12.72% drop. Year-to-date, the stock is down 8.91%, while the benchmark index has fallen 14.70%. However, Pfizer’s longer-term returns remain positive, with a 1-year gain of 9.81% versus the Sensex’s 5.47% loss, and a 3-year return of 29.09% outperforming the Sensex’s 25.50%. The 5-year and 10-year returns show a mixed picture, with Pfizer lagging the Sensex over five years but outperforming substantially over a decade.

Technical Trend Shift: From Mildly Bearish to Bearish

The technical trend for Pfizer has shifted from mildly bearish to outright bearish, signalling a deterioration in price momentum. This shift is corroborated by multiple technical indicators across different timeframes.

The Moving Average Convergence Divergence (MACD) indicator remains bearish on the weekly chart and mildly bearish on the monthly chart, indicating that downward momentum is entrenched but may be less severe over longer periods. The Relative Strength Index (RSI) shows no clear signal on either weekly or monthly charts, suggesting that the stock is neither oversold nor overbought, but the absence of bullish RSI momentum adds to the cautious stance.

Bollinger Bands reinforce the bearish outlook, with both weekly and monthly signals indicating downward pressure. The stock price is likely trading near or below the lower band, reflecting increased volatility and potential continuation of the downtrend.

Moving Averages and KST Confirm Bearish Bias

Daily moving averages are firmly bearish, with the stock trading below key averages such as the 50-day and 200-day moving averages. This alignment suggests that short-term and medium-term price trends are negative.

The Know Sure Thing (KST) indicator, a momentum oscillator, is bearish on the weekly timeframe and mildly bearish on the monthly timeframe. This confirms that momentum is weakening, although the monthly mild bearishness hints at some potential for stabilisation in the longer term.

Volume and Trend Analysis

On-Balance Volume (OBV) presents a mixed picture. While the weekly OBV shows no clear trend, the monthly OBV is bullish, indicating that despite recent price declines, accumulation may be occurring over a longer horizon. This divergence between price and volume could suggest that some investors are positioning for a potential rebound, though the overall technical environment remains cautious.

Dow Theory analysis shows no definitive trend on either weekly or monthly charts, reflecting uncertainty in the broader market context for Pfizer.

Mojo Score and Grade Downgrade

Pfizer Ltd.’s current Mojo Score stands at 37.0, categorising it as a ‘Sell’ with a small-cap market cap grade. This represents a downgrade from its previous ‘Hold’ rating as of 29 Dec 2025. The downgrade reflects the deteriorating technical parameters and the stock’s underperformance relative to broader market benchmarks in the short term.

Investors should note that the downgrade is driven primarily by technical factors rather than fundamental changes, signalling caution but not necessarily a fundamental weakness in the company’s business.

Comparative Sector and Market Performance

Within the Pharmaceuticals & Biotechnology sector, Pfizer’s bearish technical signals contrast with some peers that have maintained more stable momentum. The sector itself has faced headwinds due to regulatory uncertainties and pricing pressures, which may be contributing to Pfizer’s technical weakness.

Relative to the Sensex, Pfizer’s recent returns have been mixed. While it has outperformed the benchmark over the one-year and three-year periods, its short-term underperformance and technical deterioration suggest that investors should monitor the stock closely for signs of further weakness or potential recovery.

Key Technical Levels to Watch

Support levels near the 52-week low of ₹3,742.90 may provide a floor if selling intensifies. Resistance is likely to be encountered near recent highs around ₹4,995.00 and the 52-week high of ₹5,987.65. The stock’s ability to reclaim and sustain above key moving averages will be critical for any reversal of the current bearish trend.

Given the bearish MACD and moving averages, a sustained break below current support levels could accelerate the downtrend, while stabilisation above these levels might signal a potential consolidation phase.

Investor Takeaway

Pfizer Ltd.’s recent technical deterioration and downgrade to a ‘Sell’ rating warrant a cautious approach. The bearish signals from MACD, moving averages, Bollinger Bands, and KST suggest that the stock is under significant selling pressure. While the monthly OBV’s bullish indication hints at some underlying accumulation, the absence of strong RSI signals and Dow Theory trends implies uncertainty.

Investors should closely monitor key support levels and watch for any signs of technical reversal before considering new positions. Given the stock’s mixed long-term performance relative to the Sensex, a strategic approach that balances risk and reward is advisable.

Overall, Pfizer Ltd. currently faces a challenging technical environment that may persist until clearer signs of momentum improvement emerge.

Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Start Today